IntroductionPancreatic cancer (PC) is the fourth most lethal form of cancer in Western society, with mortality closely mirroring incidence and an overall 5-year survival of less than 7%. 1,2 Upon diagnosis, only 20% of patients are eligible for surgery, the only potential cure to date, with the remainder in advanced stages of the disease.Surgery is invasive due to the physical location of the pancreas and is often used as a treatment option in combination with chemotherapy. Despite this, a majority of patients who undergo surgery suffer a relapse from metastatic disease or experience comorbidities such as venothromboembolic disease. 3-5 Chemotherapy for PC patients involves treatment with agents such as the standard chemotherapeutic anti-metabolite drug gemcitabine (a pyrimidine analogue), or adjuvant therapy with additional agents such as the anti-tubulin agent nab-paclitaxel that can block nuclear division, causing cell death. 3,6,7 Combination drug 5-fluorouracil/folinic acid, irinotecan and oxaliplatin (FOLFIRINOX) is also a common treatment option but despite better response and survival rates than with single-agent gemcitabine treatment, FOLFIRINOX has greater levels of toxicity. 3 Chemotherapy outcomes are varied due to physical and genetic obstacles of PC that cause complications, as they can Keywords: Bitter melon; Pancreatic cancer; Herbal medicine. Abbreviations: AE, aescin equivalent; BMJ, bitter melon juice; CCK-8, Cell Counting Kit-8; CE, crude ethanol extract; CuB, Cucurbitacin B; F1, fraction 1; F2, fraction 2; F3, fraction 3; FBS, fetal bovine serum; GI50, minimum 50% growth inhibitory concentration; HPDE, human pancreatic ductal epithelial; HPLC, high-pressure liquid chromatography; L-Glu, L-glutamine; PBS, phosphate-buffered saline; PC, pancreatic cancer; SE, saponin-enriched extract.
Cytotoxic Effect of Bitter Melon (Momordica charantia L.) Ethanol Extract and Its Fractions on Pancreatic Cancer Cells in vitro
AbstractBackground and objectives: The incidence of pancreatic cancer (PC) closely matches mortality, with current therapies ineffective often due to late diagnosis and difficulties in drug delivery. Bitter melon (Momordica charantia, Cucurbitaceae) has been traditionally used as an herbal medicine, particularly for the treatment of diabetes, in South East Asian countries. The aim of this study was to investigate the anti-PC potential of a crude ethanol extract (CE) and its enriched fractions.